glp 1 between pregnancies Increased Risk of NICU Stays for Babies Born to Mothers Prescribed GLP-1 Medications in the 90 Days Before Pregnancy Study finds no major early

However: Larger meta-analyses show no significant increase in risk after adjusting for confounders [25] Incidence appears similar to other diabetes therapies [25] Much of the observed signal likely reflects: Baseline risk (obesity, T2DM) Secondary gallstone disease In summary, pancreatitis in GLP-1 users is a rare and possible complication, but current evidence does not support a substantial increase in risk directly related to GLP-1 agents

Human clinical trials, though limited, have demonstrated a potential decrease in substance use among patients treated with GLP-1RAs, particularly for alcohol and tobacco use disorders

GLP-1 signals the brain to reduce appetite while enhancing the feeling of fullness after meals, helping to moderate overall calorie intake

However, most trials recruited relatively healthy, non-drinking or light-drinking populations, so data specifically examining heavy drinkers on GLP-1 therapy is limited

Natravor GLP-1 Natravor GLP-1 Natravor GLP-1 Natravor GLP-1 Natravor GLP-1 Natravor GLP-1